Local anaesthetics (LA) have been used safely for spinal anaesthesia for 100 years. Continuous spinal anaesthesia (CSA) is considered a safe, reliable and effective technique 1 that allows incremental dosing of intrathecal LA over an indefinite duration. Ropivacaine can be used in CSA for intraoperative and postoperative analgesia 2 . The main advantage of intrathecal ropivacaine is faster recovery of motor function compared with bupivacaine 3, 4 .
The adverse effects of LAs used for spinal anaesthesia include transient neurological syndrome, which may be related to neurotoxicity 5, 6 . There is evidence that ropivacaine causes the least neurotoxicity 7 , although conclusions about the safety of intrathecal ropivacaine cannot be made due to the small number of patients who have participated in human studies 8, 9 . The potential for neurotoxicity in the context of continuous infusion techniques in humans is also unknown. Previous studies suggest the possibility of neurotoxicity from excessive doses or a prolonged duration of exposure 10 , and hyperbaricity may also be a factor when small gauge microspinal catheters are used 11 .
We previously demonstrated in a rat model that ropivacaine CSA for 48 hours can induce neurotoxicity and trigger apoptosis in a dose-dependent manner 12 .
In the context of CSA, in this current animal study across a period of 28 days, we investigated ropivacaine neurotoxicity following repeated intrathecal drug administration over 12 hours. We hypothesised that neuronal expression of protein kinase B (Akt) might be important in neuronal damage 13, 14 .
MATERIALS AND METHODS
Male Sprague-Dawley rats weighing 280-320 g were used in the experiment. The study was approved by the Ethics Committee for Animal Research of Xiang Ya Hospital in Central South University, P. R. China. Prior to the experiment, the rats were housed, two per cage, for one week in the animal facility, with a 12:12 hour dark-light cycle. Water and food were available at all times.
SUMMARY
Previous studies have shown that ropivacaine is the least neurotoxic local anaesthetic. Most of the data derive from short-term ropivacaine injection into the subarachnoid space. Intrathecal administration for a prolonged period, and the histological changes and behavioural effects of repeated intrathecal administration, have not previously been investigated. We studied the possible neurotoxicity of intrathecal injection of ropivacaine in a rat model. Rats received 0.12 ml/kg body weight of ropivacaine at concentrations of 0.5 or 1%, or normal saline only, via an implanted intrathecal catheter at 90-minute intervals for 12 hours. On days 1, 3, 5, 7, 14 and 28, the spinal cord was examined by light and electron microscopy at the L3 level. We assessed sensory thresholds to noxious stimulation, behavioural change and protein kinase B immunoreactivity for possible neuronal injury within the spinal cord.
Ropivacaine 1% induced thermal hyperalgesia and mechanical allodynia, neuronal injury characterised by tissue oedema, proliferation of glial cells, neuronal morphology changes and degeneration and protein kinase B expression. There were no significant differences in motor function as a result of different concentrations of ropivacaine.
Repeated intrathecal injection of ropivacaine 1% can induce neurotoxicity in rats. Our data suggests that expression of protein kinase B might be involved in this neurotoxicity. Surgical procedure for intrathecal catheterisation Rats were anaesthetised with chloral hydrate 10%. Based on a published method 15 , a polyurethane microspinal catheter (inner diameter 0.12 mm, outer diameter 0.35 mm) was inserted through the L5/L6 intervertebral space to lie at the L3 level. The cannulated rats were observed for five days. Fifteen rats showed symptoms of traumatic nerve injury or signs of neurological impairment as a result of catheterisation and were excluded from further experiment.
Intrathecal drug administration
The 108 remaining rats were randomly divided into three groups of 36 each. As in our previous study 12 , rats received 0.12 ml/kg body weight of ropivacaine 0.5 or 1% (AstraZeneca, Sweden), or saline only, in eight injections at 90-minute intervals across a period of 12 hours. The regimen of intermittent drug injection with a dosing interval of 1.5 hours was based on previous studies 16, 17 . The catheter was capped with a pin. Each group of rats was observed on days 1, 3, 5, 7, 14 and 28 (n=6 at each time point) after study solution administration ( Table 1) .
Neurological function tests Behavioural assessment
The hind paw withdrawal latency (WL) to noxious radiant heat and withdrawal threshold (WT) to an Electronic von Frey ® (IITC Life Science Instruments, California, USA) probe were determined for each rat before study drug administration (baseline, day 0) and once daily on days 1, 3, 5, 7, 14 and 28. Measurements were repeated three times on both the right and left paws in each rat. All tests were performed between 2pm and 5pm hours by an investigator who was blinded to the group allocation.
Thermal threshold
Rats were habituated to the surrounding environment for 30 minutes. WL was measured using Hargreaves apparatus (Ugo Basile, Comerio, Italy). Each rat was placed separately on a 3 mm thick, temperature-controlled glass floor, under which a light box was located. Light intensity was preset to obtain a baseline latency of approximately 12 seconds and a cut-off was set at 20 seconds to avoid tissue damage. The movable radiant heat source beneath the glass floor was focused on the plantar surface of the hind paw. Three WLs were collected over at least a five-minute interval and averaged.
Mechanical threshold
Rats were placed in a transparent plastic dome with a metal mesh floor that allowed access to the plantar surface of the hind paw. WT was determined using the Electronic von Frey apparatus 18 to quantify mechanical sensitivity of the foot. The Electronic von Frey probe was pressed perpendicular to the plantar surface of the hind paw with continuous force. A positive response was noted if the hind paw was sharply withdrawn and the force was recorded on the screen simultaneously. Three WTs were collected and averaged.
Motor function assessment
Motor function was measured before the daily nociceptive behavioural assessments by assessing the animal's ability to ambulate with normal posture.
Perfusion fixation and tissue preparation
After the neurological function testing had been completed, the animals were euthanased. The lumbar spinal cords were removed en bloc and each was dissected into three gross samples: the posterior corner section of lumbar spinal cord at L3 (sample 1) for electron microscopic examination (EME), a transverse section of lumbar spinal cord at L3 (sample 2) for light microscopic examination, and the posterior corner section at L3 (sample 3) for Akt examination.
The posterior corner sections of sample 1 were immersed in 2.5% glutaraldehyde phosphate buffer. Ultra-thin sections (70 to 80 nm) of sample 1 were double-stained with lead citrate and uranyl acetate and examined using 80 kV of a Hitachi H-7500 electron microscope. Sample 2 was embedded in paraffin Saline 36 and sectioned. The 10 μm thick sections were stained with eosin and haematoxylin, and the histopathologic changes were quantified; isolated lesions were not considered to be ropivacaine-related 16 . The grade of distribution score (D-score) of the lesions seen on light microscopic examination, plus the severity score (S-score) of the lesions on EME, gave the total nerve injury score 19 .
Immunohistochemistry
Staining of the neuronal marker Akt was performed to evaluate injury to neurons after ropivacaine. Akt is one of the most frequently described markers used to detect cerebral neuron injury because the constitutively expressed Akt is up-regulated in parallel to the activation-induced morphological change of cerebral neuron injury 20, 21 . The posterior corner sections of sample 3 were cut transversely by cryostat into 10 μm floating sections which were treated with 0.3% hydrogen peroxide for at least 15 minutes. Non-specific binding was blocked by 2% bovine serum plus 3% normal goat serum albumin for one hour in phosphate buffered saline with Tween 20 (PBST). Sections were incubated at room temperature overnight with 3% normal goat serum plus primary mouse monoclonal antibody (anti-Akt, 1:200; Santa Cruz Biotechnology, Santa Cruz, USA) in PBST. Sections were washed three times and incubated with goat anti-mouse biotinylated secondary antibody (1:600; Cell Signaling, Beverly, USA) for one hour. The sections were washed three more times with PBST. Then avidin-biotin-horseradish peroxidase complex (Pierce, Rockford, Ⅲ) in PBST was applied in a 1:150 dilution to floating sections for one hour. Antigens were visualised by combining equal volumes of an ammonium nickel sulphate solution and a diaminobenzidine solution in the presence of 0.01% hydrogen peroxide. Floating sections were spread flat on slides and dehydrated. Sections were cover-slipped with Permount mounting medium (Merck, Darmstadt, Germany). Assessments of Akt expression were performed on three sections chosen at random from the posterior corner section of L3. Images were acquired with a Leica 400 light microscope (Leica Microsystems GmbH, Wetzlar, Germany). The number of Akt immunoreactions in the posterior corner sections of the cord was measured under 200× magnification.
Statistical analysis
All behavioural data were expressed as mean (standard deviation [SD]). Two-way analysis of variance with post hoc Tukey test was used to compare the behavioural data of different experimental groups. Nerve injury scores are presented as median (10th to 90th percentiles) and compared using the Kruskal-Wallis test followed by the Mann-Whitney U-test. Image analysis data were compared between groups with one-way analysis of variance (ANOVA), with post hoc Bonferroni correction. P <0.05 was considered statistically significant.
RESULTS
The rats did not show any signs of clinical complications of the central nervous system (i.e. irritability, convulsions, coma, paralysis or death). Post-mortem examination confirmed that all catheters were sited correctly. Two rats were excluded from the study due to respiratory changes when ropivacaine 1% was injected. Four rats were 
A) B)
excluded because polynuclear proliferation was observed at the intrathecal catheter insertion site, this being attributed to the surgical implantation of the catheter.
Neurological function analysis
Paw stimulation test analysis
Paw withdrawal observed and measured as WL and WT (Figure 1 ). As illustrated in Figures 1A and 1B on days 1, 3, and 5 after exposure to ropivacaine 1% the WL and WT significantly increased, indicating the development of thermal hyperalgesia and mechanical allodynia. The WL and WT of the ropivacaine 1% group were significantly increased compared to the ropivacaine 0.5% and saline groups (P <0.05). Intrathecal injection of ropivacaine 1% did not alter the WLs and WTs on days 7, 14, and 28.
Motor function evaluation
Rats receiving either concentration of ropivacaine were able to ambulate within 60 minutes and recovered fully. Motor dysfunction was not observed after either saline or ropivacaine.
Neurotoxicity assessment
Light microscopic examination abnormalities were only observed in the ropivacaine 1% group. The histological changes were observed mainly in the posterior root and the adjacent posterior white matter of the spinal cord. The histological abnormality was a lesion with tissue oedema, proliferation of glial cells, vacuolation of myelin sheaths and axons, and neuronal morphology changes. Similarly, EME abnormalities were also observed only in the ropivacaine 1% group. The changes included widespread local oedema, abnormal neuronal morphology and degeneration of neurons in the posterior spinal cord ( Figure 2C to 2H). The EME was normal in the saline group (Figure 2A) . The nerve injury scores in the ropivacaine 1% group were significantly higher than those in the ropivacaine 0.5% or saline groups across all days (P=0.02, Table 2 ). Saline 6 0(0,0) 0(1,0) 0(0,0) 0(0,0) 0(0,0) 0(0,0) R 0.5% 6 0(1,0) 0(0,0) 0(1,0) 0(0,0) 0(0,0) 0(0,0) R 1% 6 2(2,2)*# 2.5(3,2)*# 4(3,4)*# 3(2,4)*# 2(1,2)*# 1.5(2,1)*# Nerve injury scores are median (10th, 90th percentiles). Nerve injury scores were calculated as the sum of D-score and S-score after an intermitted infusion of saline or ropivacaine for 12 hours on days 1, 3, 5, 7, 14 and 28. Nerve injury scores are compared using the Kruskal-Wallis test followed by the Mann-Whitney U-test.* P <0.02, versus saline group, # P <0.02, versus R 0.5% group. R=ropivacaine.
The injury scores peaked on day 5 and were maintained until day 28.
Up-regulated expression of neuronal Akt
Figures 3A to 3H show the Akt image ready (IR), on days 1, 3, 5, 7, 14 and 28, taken from the posterior corner of the cord in those rats given ropivacaine 1%. In contrast to the saline and ropivacaine 0.5% treated rats, a remarkably increased Akt IR was observed. Figure 3I shows the image analysis data of spinal Akt IR after ropivacaine or saline. In the saline group, the number of Akt IR cells present was 13 (SD 2). In the ropivacaine 0.5% group, this number was 14 (SD 2), and in the ropivacaine 1% group, the number of cells was increased to 41 (SD 3), 44 (SD 3), 39 (SD 3), 27 (SD 2), 24 (SD 3) and 19 (SD 2) on days 1, 3, 5, 7, 14 and 28 respectively. The Akt expression peaked on day 3 and the increase was maintained on day 28.
DISCUSSION
Ropivacaine is licenced for intrathecal use, but data on neurotoxicity after spinal injection are not available in humans. Previous studies have demonstrated that, like other LAs, ropivacaine has the potential to induce neurotoxicity in neuronal or non-neuronal cells in animal models. Lirk et al observed that ropivacaine and bupivacaine did not differ in neurotoxicity on dorsal root ganglion neurons 22 . Yamashita et al suggested that ropivacaine has the lowest neurotoxicity profile among the LAs tested 23 , however Malinovsky et al observed that intrathecal ropivacaine of various modes with intermittent injection or continuous infusion did not induce any neurotoxicological lesions in rabbits after seven days 16 . Our previous study found that after 48 hours exposure to CSA, ropivacaine induced neuronal injury within the spinal cord 12 .
In this experiment, we used a rat model for repeated intrathecal administration of ropivacaine for 12 hours and examined the dose-dependent and time-dependent effects on neurons on days 1, 3, 5, 7, 14 and 28 after exposure. The regimen of intermittent drug injection was similar to that employed by Rose et al 17 and was consistent with the pharmacokinetic characteristics of ropivacaine. Different injection modes (continuous infusion versus intermittent injection) do not appear to affect intrathecal ropivacaine toxicity 16, 24 . Many neurotoxicity studies have been conducted under different conditions with exposure times ranging from ten minutes to seven days. We evaluated the effect of long-term exposure to two high concentrations of ropivacaine. Concentrations of ropivacaine were chosen based on typical clinical application (0.5%) and the maximal commercial concentration (1%). As the volume of cerebrospinal fluid in the rat is very small, a highly concentrated LA solution would be expected to result in high intrathecal concentrations in direct contact with spinal cord and nerves. We hypothesised that the neurotoxicity of ropivacaine was time and concentration-dependent. In addition, in order to study the neurotoxicity of ropivacaine in the spinal cord rather than in the cauda equina, we threaded the catheter from L5/L6 up to L3.
Although neurological complications have been observed with different LAs, lignocaine causes the highest incidence of transient neurological symptoms and arguably cauda equina syndrome. Ikeya reported that ropivacaine caused lower limb sensory disturbance when used for continuous epidural anaesthesia 25 . Our experimental observation of histological changes within the spinal cord on days 1, 3, 5, 7, 14 and 28 after exposure to ropivacaine 1% were similar to those seen after lignocaine, the neuronal injury being mainly in the posterior spinal cord. The injury characteristics were similar to those observed after lignocaine 19 , possibly due to the similarity of their chemical structure. On days 7 and 28 these pathological changes improved, but did not fully recover, in our study.
We also found that repeated intrathecal injection of ropivacaine 1% significantly increased the threshold of thermal hyperalgesia and mechanical allodynia on days 1, 3 and 5. This finding was consistent with the pathological changes in the spinal cord. However, established hyperalgesia and allodynia resolved over the later days. Even after ropivacaine 1%, recovery of motor block occurred within 60 minutes and there were no significant changes in motor function thereafter. The concentration required to induce excitation, conduction and inhibition of ion channel activity in peripheral nerves and spinal cord neurons is much lower than the concentration we administered. The higher concentrations of LAs used in our study could be sufficient to cause LA-induced neurotoxicity in sensory and motor functions 10 .
The induced Akt expression observed after ropivacaine 1% occurred in neurons adjacent to the histological injury. Akt expression is thought to play a pivotal role in regulation of cellular activity and survival 26 and may be involved in the protection of damaged neurons 27 . On the other hand, Akt is up-regulated when there is accompanying neuronal injury. In our study, Akt was up-regulated in the posterior corner sections of the rat spinal cord. The biochemical changes caused by ropivacaine may be a factor that triggers Akt up-regulation. Another may be excitatory signals from injured neurons, but further formal neurotoxicity testing is necessary.
LAs have been used to provide long-term intrathecal analgesia in patients 28 . No previous study investigated the neurotoxic potential of prolonged intrathecal ropivacaine administration. Our data showed that ropivacaine 1% induced neuropathological changes on all observed days, induced sensory function changes on days 1, 3, 5 and up-regulated Akt expression in spinal cord neurons.
In conclusion, repeated dosing of intrathecal ropivacaine induces neurotoxicity in a dose-dependent manner in a rat model and Akt up-regulation may be a manifestation of this neurotoxicity.
